Nkarta
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 150
- Market Cap
- $379.6M
- Website
- http://www.nkartatx.com
- Introduction
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
- Conditions
- Systemic SclerosisIdiopathic Inflammatory MyopathiesAntineutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06733935
- Locations
- 🇺🇸
Nkarta Investigational Site, Houston, Texas, United States
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)
- Conditions
- GlomerulonephritisLupus Nephritis
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06557265
- Locations
- 🇺🇸
Nkarta Investigational Site, Houston, Texas, United States
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- Conditions
- Lymphoma, Non-HodgkinLarge B-cell LymphomaMantle Cell LymphomaB-cell Acute Lymphoblastic LeukemiaIndolent LymphomaSmall Lymphocytic LymphomaLarge-cell LymphomaWaldenstrom MacroglobulinemiaAggressive LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05020678
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇦🇺Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
- Conditions
- MDSAML, AdultRelapsed/Refractory AMLRefractory Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04623944
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States